Description:
This study examines the use of cryoablation as an alternative to surgery in the treatment of
early stage invasive breast cancer. The hypothesis is that cryoablation will complete
ablation and destroy the tumor in a selected population of women who may otherwise be
adequately treated with surgery.
Title
- Brief Title: Cryoablation of Small Breast Tumors in Early Stage Breast Cancer
- Official Title: Freezing Alone Instead of Resection Of Small Breast Tumors: A Study of Cryoablation in the Management of Early Stage Breast Cancer
Clinical Trial IDs
- ORG STUDY ID:
CP-00-0011
- NCT ID:
NCT01992250
Conditions
Purpose
This study examines the use of cryoablation as an alternative to surgery in the treatment of
early stage invasive breast cancer. The hypothesis is that cryoablation will complete
ablation and destroy the tumor in a selected population of women who may otherwise be
adequately treated with surgery.
Detailed Description
PURPOSE:
To determine the rate of successful tumor ablation in patients treated with cryoablation and
endocrine therapy in a subset of patients with early stage breast cancer.
OUTLINE:
1. Core Biopsy (Pre-Registration)
2. Magnetic Resonance Imaging (Pre-Registration)
3. Tumor Cryoablation
4. Core Biopsy (Post-Cryoablation)
5. Magnetic Resonance Imaging (Post-Cryoablation)
6. Postoperative Follow-up
7. Evaluation of outcomes
Trial Arms
Name | Type | Description | Interventions |
---|
Low Risk - Age 70+ | Other | Age 70+. Patients treated with the Visica 2 Treatment System, followed by adjuvant therapies | |
Moderate Risk - Age 50-69 | Other | Age between 50-69. Patients treated with the Visica 2 Treatment System, followed by adjuvant therapies | |
Eligibility Criteria
Inclusion Criteria:
1. Age ≥ 50
2. Unifocal primary invasive breast carcinoma diagnosed by core needle biopsy
3. Maximum tumor size ≤1.5 cm in its greatest diameter
4. Ultrasound visible lesion(s)
5. Clinically node negative, hormone receptor positive (+). HER2 negative (-), with <25%
intraductal component in the aggregate.
6. Unilateral or bilateral disease meeting study criteria
7. Physical and emotional ability to undergo baseline and follow-up breast MRIs and
serial breast cosmesis analysis
8. Patient agrees to receive a 5 year minimum course of endocrine therapy following
cryoablation for control of systemic disease
Exclusion Criteria:
1. Prior treatment (e.g., open surgical biopsy, lumpectomy) of index cancer
2. Ductal carcinoma in-situ with microinvasions (T1mic)
3. Multifocal or multicentric invasive breast carcinoma
4. Prior or planned neoadjuvant systemic therapy for breast cancer
5. Tumor with ≥25% IDC components
Maximum Eligible Age: | N/A |
Minimum Eligible Age: | 50 Years |
Eligible Gender: | Female |
Healthy Volunteers: | No |
Primary Outcome Measures
Measure: | Tumor ablation occurence |
Time Frame: | Within 6 months |
Safety Issue: | |
Description: | Successful tumor ablation will be defined as absence of residual viable invasive or in situ carcinoma. Will be determined at 6-month post-cryoablation biopsy. Residual disease will require surgery. |
Secondary Outcome Measures
Measure: | Local tumor recurrence |
Time Frame: | Within 5 years |
Safety Issue: | |
Description: | |
Measure: | Satisfactory breast cosmesis results |
Time Frame: | 5 Years |
Safety Issue: | |
Description: | |
Measure: | Adverse event assessment |
Time Frame: | 5 years |
Safety Issue: | |
Description: | |
Details
Phase: | N/A |
Primary Purpose: | Interventional |
Overall Status: | Recruiting |
Lead Sponsor: | Sanarus Technologies, Inc. |
Trial Keywords
Last Updated
April 20, 2018